Sona Nanotech

Overview

Halifax, Nova Scotia-based Sona Nanotech’s (CSE:SONA,OTCQB:SNANF) patented nanoparticle manufacturing processes have allowed it to develop an innovative cancer therapy that can shrink tumors from the inside out, and in so doing, enables standard immunotherapy drugs to work significantly better and potentially on patients for whom no other treatment has worked. Sona’s gold nanorod manufacturing technology uniquely does not rely on the use of toxins, making them an ideal agent to be intratumorally injected in humans which can be used to generate therapeutic heat in the tumor.

Sona’s therapy will be applied to the late-stage melanoma tumors that cannot safely be resected and for which no other therapy has worked. Once Sona’s gold nanorods are injected into a tumor, Sona’s laser directs non-thermal, near infrared light energy that is tuned to the same wavelength as the gold nanorods. The gold nanorods react by vibrating, turning the light energy into heat, killing the cancer cells selectively and causing apoptosis in their cells, resulting in the release of new antigens into the system. These new antigens prime the innate immune system permitting immune-oncology drugs to be more effective at eliminating the treated tumor and can serve as a tumor specific vaccine for the body, attacking distant tumors that were not treated, acting much like a vaccine does.

Sona’s board includes the key builder of vaccine maker Sanofi-Pasteur, a Khosla Ventures biotech PhD CEO and a long-time president of Medtronic Canada. Its management team includes an experienced capital markets CEO, CSO with a PhD, and a CMO who is a highly experienced surgical oncologist and researcher.